



Ref: FOIA Reference 2022/23-641

Royal Stoke University Hospital
Data, Security and Protection
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 17th February 2023

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 6th February 2023 requesting information under the Freedom of Information Act (2000) regarding AML and CLL

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Please see below a Freedom of Information request made by [REDACTED] Please answer the questions with regards to NHS patients, i.e., excluding patients that receive treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.

A1 33

Q2 What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?

A2 50mg

Q3 What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)

A3 14

Q4 What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?

A4 Three months

Q5 Patients with chronic lymphocytic leukaemia (CLL)

Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.

Note: please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months			
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*			
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months			

*We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.

A5 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months	25	10	<5

Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*	100mg	100mg	100mg
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months	8	<5	11

Q6 Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)
Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months				

⚡ **Note:** There are five different pack sizes of venetoclax available in the UK:

- Pack 1: venetoclax 10 mg x 14 tablets
- Pack 2: venetoclax 50 mg x 7 tablets
- Pack 3: venetoclax 100 mg x 7 tablets
- Pack 4: venetoclax 100 mg x 14 tablets
- Pack 5: venetoclax 100 mg x 112 tablets

A6 See below:

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10	1	1	1	0

mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months				
---	--	--	--	--

Q7 Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

A7 As per Blueteq Criteria and SPC

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust’s disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust’s FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner’s Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Rachel Montinaro
Data Security and Protection Manager - Records